Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Capital Expenditures (2016 - 2025)

Sangamo Therapeutics has reported Capital Expenditures over the past 16 years, most recently at -$14000.0 for Q4 2025.

  • Quarterly results put Capital Expenditures at -$14000.0 for Q4 2025, up 90.85% from a year ago — trailing twelve months through Dec 2025 was $74000.0 (down 68.64% YoY), and the annual figure for FY2025 was $74000.0, down 68.64%.
  • Capital Expenditures for Q4 2025 was -$14000.0 at Sangamo Therapeutics, down from -$13000.0 in the prior quarter.
  • Over the last five years, Capital Expenditures for SGMO hit a ceiling of $16.2 million in Q4 2022 and a floor of -$14.6 million in Q3 2021.
  • Median Capital Expenditures over the past 5 years was $110500.0 (2025), compared with a mean of $1.1 million.
  • Biggest five-year swings in Capital Expenditures: soared 1735.48% in 2022 and later tumbled 392.59% in 2025.
  • Sangamo Therapeutics' Capital Expenditures stood at $885000.0 in 2021, then soared by 1735.48% to $16.2 million in 2022, then tumbled by 114.22% to -$2.3 million in 2023, then surged by 93.38% to -$153000.0 in 2024, then skyrocketed by 90.85% to -$14000.0 in 2025.
  • The last three reported values for Capital Expenditures were -$14000.0 (Q4 2025), -$13000.0 (Q3 2025), and -$133000.0 (Q2 2025) per Business Quant data.